JANEX-1

JANEX-1 (WHI-P131) is a potent and specific JAK3 inhibitor (estimated Ki=2.3 μM) . JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC50 of 78 μM), does not inhibit JAK1 and JAK2.

Product Specifications

CAS Number

[202475-60-3]

Product Name Alternative

WHI-P131; Jak3 inhibitor I

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/JANEX-1.html

Concentration

10mM

Purity

99.63

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1

Molecular Formula

C16H15N3O3

Molecular Weight

297.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5 (6) :1569-82.|[2]Oh YB, et al. Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice. Exp Mol Med. 2013 May 17;45:e23|[3]Uckun FM, et al. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4- (4'hydroxyphenyl) -amino-6,7- dimethoxyquinazoline. Clin Cancer Res. 1999 Oct;5 (10) :2954-62.|[4]Xia F, et al. IL4 (interleukin 4) induces autophagy in B cells leading to exacerbated asthma. Autophagy. 2018;14 (3) :450-464.